Shopping Cart
- Remove All
Your shopping cart is currently empty
Margetuximab
🥰Excellent
Catalog No. T76689Cas No. 1350624-75-7
Alias MGAH-22, MGAH22
Margetuximab (MGAH-22) is a second generation anti-human epidermal growth factor receptor 2 protein (HER2) monoclonal antibody with anti-tumor activity for the study of metastatic HER2-positive breast cancer and for the synthesis of nanomedicines.
Margetuximab
Margetuximab
🥰Excellent
Purity: 95%
Catalog No. T76689Alias MGAH-22, MGAH22Cas No. 1350624-75-7
Margetuximab (MGAH-22) is a second generation anti-human epidermal growth factor receptor 2 protein (HER2) monoclonal antibody with anti-tumor activity for the study of metastatic HER2-positive breast cancer and for the synthesis of nanomedicines.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $183 | In Stock | |
| 5 mg | $448 | In Stock | |
| 10 mg | $728 | In Stock | |
| 25 mg | $1,080 | In Stock | |
| 50 mg | $1,480 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Margetuximab"
Tannic acid
Cited
Gallotannic acid
T08011401-55-4
Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
- $41
Size
QTY
CitedNeratinib Cited
HKI-272
T2325698387-09-6
Neratinib (HKI-272) (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor for HER2 and EGFR (IC50: 59/92 nM), respectively.
- $30
Size
QTY
CitedAfatinib Dimaleate Cited
BIBW2992, BIBW 2992MA2, Afatinib (BIBW2992) Dimaleate, Afatinib
T1773850140-73-7
Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.
- $34
Size
QTY
CitedTucatinib Cited
ONT-380, Irbinitinib, ARRY-380
T2364937263-43-9
Tucatinib (ONT-380) is a potent and selective HER2 inhibitor (IC50: 8 nM).
- $30
Size
QTY
CitedAG-1478 Cited
Tyrphostin AG-1478, NSC 693255, AG1478
T2047153436-53-4
AG-1478 (NSC-693255) (Tyrphostin AG-1478) is a selective EGFR inhibitor.
- $45
Size
QTY
CitedVU 0240551
TQ0139893990-34-6
VU 0240551 is a selective antagonist of neuronal K-Cl cotransporter KCC2 inhibitor with an IC50 of 560 nM. VU 0240551 inhibits L-type calcium channels and hERG.
- $31
Size
QTY
Cisapride
R 51619, Pridesia, Prepulsid, Kinestase, Kaudalit, (±)-Cisaprid
T129181098-60-4
Cisapride (R 51619) is a serotonin type 4 (5-HT4) receptor agonists are potent prokinetic agents that act on serotonin receptors in the intestine and promote intestinal peristalsis, increase gastric emptying and decrease esophageal reflux.
- $39
Size
QTY
(S)-Afatinib Cited
BIBW2992
T2303439081-18-2
(S)-Afatinib (BIBW2992) is an irreversible EGFR family inhibitor with IC50s of 0.5/0.4/10/14/1 nM for EGFRwt, EGFR (L858R), EGFR (L858R/T790M), HER2, and HER4, respectively.
- $30
Size
QTY
CitedPyrotinib dimaleate
SHR-1258 dimaleate
T125941397922-61-0In house
Pyrotinib dimaleate is a selective EGFR/HER2 dual inhibitor with IC50 values ​​of 13 and 38 nM, respectively, for the treatment of HER2-positive breast cancer.
- $157
Size
QTY
Mollugin
Rubimaillin
T367355481-88-4
Mollugin (Rubimaillin) may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin as a candidate for a chemotherapeutic agent in OSCCs via the upregulation of the HO-1 and Nrf2 pathways and the downregulation of NF- κ B. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Also, it has anticancer efficacy, can modulate the HER2 pathway in HER2-overexpressing Y cells with a potential role in the treatment and prevention of human breast and ovarian Y with HER2 overexpression.
- $39
Size
QTY
AG1557
AG-1557, AG 1557
T2034189290-58-2
AG1557 (AG-1557) is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (pIC50: 8.194).
- $41
Size
QTY
Terodiline
T6053615793-40-5In house
Terodiline is a seconal amine with anticholinergic and calcium antagonistic properties that blocks the hERG current (IC50: 375 nM).Terodiline is cardiotoxic and has been used in the study of disorders caused by urethral muscle instability.
- $293
Size
QTY
Select Batch
Concentration:14.34 mg/mL
Purity:95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Margetuximab (MGAH-22) is a second generation anti-human epidermal growth factor receptor 2 protein (HER2) monoclonal antibody with anti-tumor activity for the study of metastatic HER2-positive breast cancer and for the synthesis of nanomedicines. |
| Targets&IC50 | HER2:39.33 ng/mL (EC50) |
| In vitro | Margetuximab is a chimeric anti-HER2 monoclonal antibody with an optimized Fc structural domain and an EC50 value of 39.33 ng/mL.Margetuximab enhances the activity of effector cells against antibody-mediated cellular cytotoxicity (ADCC) mediated by antibody-dependent cells expressing the CD16A-158F variant. [1] |
| In vivo | In a mouse model, weekly intraperitoneal injections of 2-4 mg/kg of Margetuximab (5-6 times) demonstrated significant tumor shrinkage on days 30-37.[1] Margetuximab has been shown to increase tumor size in mice, and has been shown to increase tumor size in mice. [1] In a study in cynomolgus monkeys, weekly intravenous injections of 15-150 mg/kg of Margetuximab (6 doses) were well tolerated and induced a mean reduction in NK cell counts by 51% and release of IL-6. A single dose of 50 mg/kg of intravenous Margetuximab demonstrated a favorable safety profile. [1] |
| Alias | MGAH-22, MGAH22 |
| Cas No. | 1350624-75-7 |
Storage & Solubility Information
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Margetuximab | purchase Margetuximab | Margetuximab cost | order Margetuximab | Margetuximab in vivo | Margetuximab in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.